Explore our new Supplier Directory

We are committed to providing innovative and quality medicines to the nearly 200 million people we serve around the world every day; we make contact with patients, families and communities for better health and better days.

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

Headquartered in Mumbai, India, Lupin is a global pharmaceutical leader with a footprint across the U.S., LATAM, APAC, EMEA and India, with products distributed in over 100 markets. With a diverse portfolio of over 1,200 products, Lupin remains committed to its mission of making quality healthcare accessible to the communities we serve. Our visionary Founder, Dr. Desh Bandhu Gupta, instilled in us the importance of offering quality, affordable and innovative medicines and being a responsible corporate citizen, making a positive difference to patients, communities and the environment.

HEC Pharm Co has obtained approval from the FDA and EDQM as a pharmaceutical manufacturer of both active pharmaceutical ingredients (API) and dosage forms. Presently, HEC is the largest global producer of Macrolides API, including Erythromycin and its derivatives. Sunshine Lake Pharma Co, a subsidiary of HEC Pharm, was established to supply finished pharmaceuticals (dosage forms) to the markets of the United States and European Union (EU).

Alembic Pharmaceuticals Limited is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. Headquartered in Vadodara, Gujarat, we derive a third of our revenue of over $600 million from the India market.

Pfizer CentreOne® is a completely distinct global contract development and manufacturing organization (CDMO), as well as a prominent provider of specialty APIs and intermediates. Supported by resources from Pfizer, we have provided technical knowledge, regulatory assistance, and long-term supply for more than 40 years. With a network of over 35 sites spanning six continents, we are capable of securely and effectively guiding complex compounds from development to commercial manufacture. For more details, please visit http://www.pfizercentreone.com

Kopran Ltd is a globally operating pharmaceutical company focused on marketing and production. The company possesses two WHO GMP approved manufacturing facilities. Their FDF facility in Khopoli is accredited by TGA, MHRA, and MCC, while their API facility in Mahad holds WHO GMP accreditation. Kopran Ltd exports its products to prominent markets in Europe, Southeast Asia, and Latin America. The company offers a diverse range of Active Pharmaceutical Ingredients (APIs) in categories such as Anti-hypertensive, Macrolides, Neuromodulator, Cephalosporins, Carbapenems, and Oncology, as well as Finished Dosage Forms in Carbapenems, Gastroenterology, Anthelmintics, Central Nervous System, Pain management, Anti-allergies, Anti-asthmatics, Anti-Infectives, Penicillins, Cardiovascular, Antiprotozoal, Oncology, Anti-Diabetics, Erectile Dysfunction, and Macrolides.

VIATRIS™ represents a fresh approach to healthcare, dedicated to ensuring medicine accessibility, promoting sustainable practices, pioneering creative remedies, and enhancing patient results. Founded in 2020 through the merger of Mylan and Upjohn, Viatris unites top-notch scientific, production and distribution skills with established regulatory, medical and commercial proficiencies.

CSPC Pharmaceutical Group Limited ("CSPC") (Stock code: 1093.HK) is a leading pharmaceutical group in China. The Company has been listed on the Main Board of the Hong Kong Stock Exchange since 1994 and became a constituent stock of the Hang Sang Index in 2018 (the 1st constituent stock in the pharmaceutical sector since launch of the index). CSPC is currently also a constituent stock of the "Hang Seng Composite Index", "Hang Seng Healthcare Index", "Hang Seng SCHK Mainland China Healthcare Index", "Hang Seng Stock Connect Hong Kong Index", "Hang Seng China (Hong Kong-listed) 100 Index" and "Hang Seng China Enterprises Index". CSPC mainly owns two business segments of finished drugs and bulk drugs, with innovative drugs as the core development strategy. CSPC currently has a strong product portfolio in the therapeutic areas of nervous system disease, oncology, anti-infective and cardiovascular disease. Of which "NBP", "Domeisu", "Jinyouli", "Keaili" and "Xuanning" are the most popular innovative drug products in China. Bulk drug products include vitamin C, antibiotics and caffeine series. The manufacturing facilities of CSPC are mainly located in Shijiazhuang City, Hebei Province, China. CSPC has a international R&D team with R&D bases in Shijiazhuang, Shanghai, Beijing and the United States, focusing on the discovery, research and development of small molecule targeted drugs, nano-drugs, monoclonal antibody drugs, bispecific antibody drugs, antibody-drug conjugates and biological drugs in the immune field.

Jubilant Ingrevia Limited is an internationally integrated provider of Life Science products and Innovative Solutions, catering to Pharmaceutical, Nutrition, Agrochemical, Consumer, and Industrial clients with tailored products and solutions that are pioneering, cost-efficient, and adhere to outstanding quality standards. Its range also encompasses personalized research and production for pharmaceutical and agrochemical customers on an exclusive basis. The organization provides a selection of over 125 products & pioneering solutions utilizing more than 35 essential chemistry and technology platforms across its three business segments of Speciality Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. With a team of over 2,100 employees serving more than 1,500 customers in over 50 countries worldwide, the company is motivated to bring value to millions of lives through innovations and state-of-the-art technology. For more information, please visit www.jubilantingrevia.com. Business Segments: Speciality Chemicals consists of distinct building blocks such as Pyridine and Picolines, Cyanopyridines, Piperidine, and their value-added derivatives. The company has recently ventured into Diketene Chemistry, currently producing Diketene esters & amide with several other Diketene derivatives in the pipeline. The Speciality Chemicals products are utilized in the production of a variety of Agrochemicals, Pharmaceuticals, Nutrition, Fine chemicals, Oilfield chemicals, Electronics, and Solvents. Nutrition & Health Solutions caters to Human & Animal Nutrition, Pharmaceutical & Personal Care segment/applications and comprises three businesses - Nutrition & Health Ingredients, Animal Nutrition & Health Solutions, and Human Nutrition & Health Solutions. Chemical Intermediates manufactures a range of Chemical Intermediates including Acetyl Products and Speciality Ethanol.

Nectar Lifesciences Limited is a research-driven, leading manufacturer of Active Pharmaceutical Ingredients (API), intermediates as well as Finished dosage forms offering largest segment of anti-infectives namely Cephalosporins. Nectar has proven to be a reliable CMO to global pharma innovators.

We are a global vertically integrated pharmaceutical company engaged in research and development, manufacture, sale and distribution of prescription and OTC pharmaceutical products, with global presence in more than 50 countries, including United States, Europe, Canada, Japan, Australia and Rest of the World. We offer a wide range of proprietary finished dosage formulation catering to different therapeutic segments, including CVS, CNS, gastro-intestinal, etc. in multiple dosage forms including: Immediate-release oral solids Modified release oral solids MUPS based products Chewable tablets Powder for oral solutions & Suspensions

Nuray Chemicals Pvt Ltd is a manufacturing facility approved by the US Food and Drug Administration (USFDA) for active pharmaceutical ingredients (API) with an advanced research and development/manufacturing site situated in Thiruvallur, near Chennai, in the state of Tamil Nadu, India. Nuray has extensive experience in launching products in the pharmaceutical industry, particularly in developing niche, novel, and challenging-to-produce APIs for commercial use, meeting chemistry requirements through synthesis.

UNIPEX, your Intelligent and Strategic associate for pharmaceutical sectors. UNIPEX proficiency lies in the delivery of ground-breaking APIs, additives, synthesis intermediates. UNIPEX provides distinctive services in close collaboration with its principals: specialized support in R&D formulation, regulatory registration, technical workshops, and tailored solutions in Benelux. DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP Unipex

Sinopharm, a significant healthcare organization affiliated with the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, operates with a workforce of 128,000 and a comprehensive industry presence encompassing research and development, production, supply chain management, retail outlets, medical services, engineering, events, international trade, and financial services. It possesses more than 1,100 subsidiaries and 6 publicly traded companies, including Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., and China National Accord Medicines Corporation Ltd.

Mehta API Pvt Ltd is involved in the production and promotion of APIs & Advanced Drug Intermediates on a global scale. Mehta Api takes great pride in its accomplishments since its establishment. Our journey is marked by numerous success stories, many of which have been unprecedented in the pharmaceutical industry. Our achievements are attested by our utmost priorities - Product Excellence and Customer service. We firmly believe that sustained business success is based on values. Upholding business ethics is essential as they function as a long-term insurance policy. We are dedicated to achieving Excellence in Product Quality and maintaining strict delivery schedules.

Established in the year 1991, SM Biomed Sdn. Bhd. is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates based out in Malaysia With our state-of-the-art manufacturing facility certified by USFDA, EDQM, EUGMP and NPRA (Malaysia), we are dedicated to improve the quality of life through developing and delivering innovative solutions and products at an affordable cost. With a legacy spanning more than three decades and pioneers for Macrolide based antibiotics, we work with customers globally with speed, efficiency and cost effective manufacturing capabilities. SM Biomed has grown as a market leader in Macrolides antibiotics and evolved into a knowledge driven company providing reliable pharmaceutical services including developing and manufacturing APIs and Intermediates. From pipeline to production, we make innovative, quality driven and customised products more accessible. We are a quality driven and R&D focused API manufacturing company with a diverse product portfolio catering various therapeutic segments.

Globela has been leading the way in innovation for almost seven decades. Originating in 2006 as a small pharmaceutical firm, Globela's current range of vertically integrated businesses is now concentrated on a variety of therapeutic areas including Gastroenterology, Cardiovascular, Diabetology, Oncology, Pain management, and Nephrology. A multinational company with EU GMP, WHO GMP, and ISO certifications, Globela also prides itself on its advanced research and development capability and high-quality compliant manufacturing facilities for a wide array of FDFs, DC Granules and Pellets (semi-finished), APIs and Intermediates, and more.

CALYX is an Active Pharmaceutical Ingredient and Intermediate manufacturer successfully inspected by the regulatory agencies of USFDA, EDQM, WHO Geneva and other accreditations for the manufacturing site located at Tarapur, Maharashtra (India).